澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

RECCE PHARMACEUTICALS LTD

0.355

-0.015-4.05%

成交量：4.04萬

成交額：1.48萬

市值：1.08億

市盈率：-6.87

高：0.370

開：0.370

低：0.355

收：0.370

52周最高：0.730

52周最低：0.345

股本：3.06億

流通股本：1.69億

量比：0.40

換手率：0.02%

股息：- -

股息率：- -

每股收益(TTM):-0.052

每股收益(LYR):-0.052

淨資產收益率：-1277.62%

總資產收益率：-82.75%

市淨率：-6.49

市盈率(LYR):-6.87

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

Recce Pharmaceuticals Ltd 研發新型合成抗感染藥物直擊耐藥超級細菌

Recce Pharmaceuticals稱HREC批准加速其全球III期DFI戰略

Recce Pharmaceuticals Ltd 獲許可方於沙特、海合會、埃及、阿爾及利亞及摩洛哥獲得R327g獨家權利

Recce Pharmaceuticals Ltd 將獲淨售價30%分成及超5000萬美元年銷售額6%特許權使用費

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/RCE.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.355,"timestamp":1789107120000,"preClose":0.37,"halted":0,"volume":40381,"delay":0,"changeRate":-0.04054054054054058,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":168893037,"shares":305520100,"eps":-0.0517,"marketStatus":"未開盤","change":-0.015,"latestTime":"09-11 16:12:00 AEST","open":0.37,"high":0.37,"low":0.355,"amount":14796,"amplitude":0.040541,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0517,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.37,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.39967258982969023,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCE.AU","preClose":0.37,"auctionPrice":0.37,"auctionVolume":80,"auction":3,"marketStatus":"盘后竞价","timestamp":1789106425279}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":168893037,"roa":"-82.75%","roe":"-1277.62%","lyrEps":-0.0517,"volumeRatio":0.39967258982969023,"shares":305520100,"dividePrice":0,"high":0.37,"amplitude":0.040541,"preClose":0.37,"low":0.355,"week52Low":0.345,"pbRate":"-6.49","psRate":"11.46","week52High":0.73,"institutionHeld":0,"latestPrice":0.355,"eps":-0.0517,"divideRate":0,"volume":40381,"delay":0,"ttmEps":-0.0517,"open":0.37,"prevYearClose":0.65,"prevWeekClose":0.355,"prevMonthClose":0.375,"prevQuarterClose":0.405,"fiveDayClose":0.37,"twentyDayClose":0.37,"sixtyDayClose":0.48,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1195921803","title":"Recce Pharmaceuticals Ltd 研發新型合成抗感染藥物 直擊耐藥超級細菌","url":"https://stock-news.laohu8.com/highlight/detail?id=1195921803","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195921803?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 08:40","pubTimestamp":1785372009,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd（简称RCE）正致力于开发一种全新类型的合成抗感染药物。这些药物旨在应对那些对现有抗生素产生耐药性的超级细菌，直击当前全球公共卫生领域的重大威胁。通过设计独特的合成分子，该公司力求在耐药性问题上实现突破，为日趋严峻的感染治疗困境提供新方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110230784","title":"Recce Pharmaceuticals稱HREC批准加速其全球III期DFI戰略","url":"https://stock-news.laohu8.com/highlight/detail?id=1110230784","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110230784?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 09:35","pubTimestamp":1782092148,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd宣布，其人类研究伦理委员会的批准将加速公司在全球范围内实施针对糖尿病足感染的III期临床试验战略。这一进展标志着公司在该关键治疗领域迈出了重要一步。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139423312","title":"Recce Pharmaceuticals Ltd 獲許可方於沙特、海合會、埃及、阿爾及利亞及摩洛哥獲得R327g獨家權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1139423312","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139423312?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 07:51","pubTimestamp":1779839482,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd 宣布，其许可合作方已获得在沙特阿拉伯、海湾合作委员会国家、埃及、阿尔及利亚及摩洛哥市场开发与商业化新型抗菌候选药物R327g的独家权利。此项授权协议的达成，标志着该公司在中东与北非关键市场的战略布局取得重要进展，有望进一步拓展其核心产品的全球覆盖范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198655607","title":"Recce Pharmaceuticals Ltd 將獲淨售價30%分成及超5000萬美元年銷售額6%特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1198655607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198655607?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 07:51","pubTimestamp":1779839475,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd 已达成一项关键商业协议。根据协议条款，该公司将有权获得其产品销售净售价的30%作为分成。此外，当年销售额超过5000万美元时，Recce还将额外获得超出部分销售额6%的特许权使用费。这一安排为该公司未来的收入流奠定了重要基础，并与其核心产品的商业化前景紧密相连。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RCE.AU\",params:#limit:6,delay:true,,,undefined,":[]}}